Blog

  • Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

    Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

    Researchers hoped the technique might involve lower exposure compared with right transradial access, but this didn’t pan out.

    SAN FRANCISCO, CA—Operators are exposed to equal amounts of radiation during coronary procedures whether they use left distal radial access (DRA) or right transradial access (TRA), according to new data from the randomized, multicenter DOSE trial.

    Yongcheol Kim, MD, PhD (Yongin Severance Hospital, Republic of Korea), who presented the data during the TCT WorldLink Forum today, said left DRA “has recently emerged as an alternative access site” that, among other things, offers operators less physical discomfort. It also involves less subclavian tortuosity plus catheter techniques that are more akin to the transfemoral approach.

    Unfortunately, as in the group’s previous DRAMI trial comparing access routes in STEMI patients, the hoped-for radiation benefits with left DRA did not pan out.

    James Goldstein, MD (Millennium Cardiology, Royal Oak, MI), the discussant following Kim’s presentation, summed up the data by saying: “I love it when trials make sense.” In DOSE, “the manner in which the left and right wrists were ultimately positioned [was] pretty much the same spot on the groin, so there’s no a priori reason to think there would be much difference in radiation exposure based on the position and the access,” he commented.

    Led by Oh-Hyun Lee, MD, and Ji Woong Roh, MD, PhD (both from Yongin Severance Hospital), the study, which was simultaneously published in JACC: Cardiovascular Interventions, is the first large, randomized trial to evaluate the potential for left DRA to limit how much radiation operators receive during these procedures. 

    Prior studies had suggested that “operators using the left TRA tend to experience less radiation exposure than those using the right TRA,” according to Kim.

    “Coronary angiography and PCI are essential procedures in the diagnosis and treatment of coronary artery disease, often performed thousands of times over an interventional cardiologist’s career,” the researchers note in their paper, adding that the radiation exposure to operators that accompanies such cases can, over a lifetime, pose substantial health risks.

    The DOSE Trial

    The DOSE investigators randomized 1,010 patients scheduled to undergo coronary procedures by either left DRA or right TRA at three centers in the Republic of Korea. They used a set of three real-time dosimeters to measure radiation exposure for five experienced operators at the left wrist, as well as at the left side of the head outside the lead cap and the left chest pocket of the lead vest. All wore the same radiation protection gear, including lead skirt and vests, thyroid collars, leaded glasses, leaded caps, and shields mounted on the table and ceiling.

    With left DRA, patients’ left hands were positioned in the same place as where the left femoral artery puncture site would be, whereas with right TRA, patients’ right arms were positioned close to the right side of their bodies.

    The left DRA group had a lower proportion of male patients and was more likely to undergo ultrasound-guided puncture. PCI, done in a quarter of the participants, trended higher with left DRA but didn’t reach statistical significance. All other baseline characteristics were similar in the two groups.

    However, radiation levels were similar at each location no matter which access route was used.

    Median Radiation Exposure (μSv) to Operators by Access Route

     

    Left DRA

    Right TRA

    P Value

    Left Wrist

    4.76

    5.20

    0.342

    Head

    2.00

    1.83

    0.416

    Chest

    1.28

    1.07

    0.199

    There were no advantages to either approach for the secondary endpoints of access-site crossover, fluoroscopy time, procedure time, and contrast volume, and no differences across patient subgroups.

    Overall, though, the study reassures “that radiation hazard should not be considered a limiting factor for the adoption of left DRA in routine clinical practice,” the researchers conclude.

    Goldstein added that both access routes were “successful, with equivalent levels of procedural performance,” however.

    Going forward, as radiation protective gear grows more sophisticated and more widely used, these issues may have less relevance, he suggested. The benefits of the newer products go beyond lower exposure to radiation. Also important, Goldstein said, is “getting the lead off and avoiding the orthopedic complications” associated with traditional protective clothing.


    Continue Reading

  • What’s Glowing at the Center of Our Galaxy? New Study Points to Dark Matter – SciTechDaily

    1. What’s Glowing at the Center of Our Galaxy? New Study Points to Dark Matter  SciTechDaily
    2. Dark matter might not be invisible after all. It could leave a hidden glow  Science Daily
    3. Mysterious glow at the Milky Way’s center could reshape a major…

    Continue Reading

  • What you get with Google AI Pro and AI Ultra [October 2025]

    What you get with Google AI Pro and AI Ultra [October 2025]

    At I/O 2025, Google One AI Premium (and Gemini Advanced) became “Google AI Pro,” while a higher, more expensive tier was introduced with “Google AI Ultra.”

    Updated 10/25

    Google AI Pro 

    AI Pro is simply a…

    Continue Reading

  • Live Updates: Saturday Night Action Around the NBA

    Live Updates: Saturday Night Action Around the NBA

    🏀Saturday’s Schedule🏀

    Top Storylines 👉📝

    – Denver and Phoenix renew their rivalry

    These teams have played three overtime games over their last 11 matchups. Nikola Jokić had one of the best performances in NBA history…

    Continue Reading

  • When your AI browser becomes your enemy: The Comet security disaster – VentureBeat

    1. When your AI browser becomes your enemy: The Comet security disaster  VentureBeat
    2. The glaring security risks with AI browser agents  TechCrunch
    3. Is it safe to use AI browsers like ChatGPT Atlas and Perplexity Comet? Researchers warn of major…

    Continue Reading

  • Health authorities warn of a measles outbreak in multiple regions of New Zealand as of October 24; exercise caution while travelling. – SafeAbroad

    1. Health authorities warn of a measles outbreak in multiple regions of New Zealand as of October 24; exercise caution while travelling.  SafeAbroad
    2. Measles cases and exposures continue to escalate  NZ Doctor
    3. ‘We should be concerned’: Why low measles…

    Continue Reading

  • Dimeco (DIMC) Profit Margin Beats Narrative With 32.2%, Reinforcing Value Investor Optimism

    Dimeco (DIMC) Profit Margin Beats Narrative With 32.2%, Reinforcing Value Investor Optimism

    Dimeco (DIMC) delivered earnings growth of 6.7% per year over the last five years, with profits accelerating to a strong 36.1% gain in the latest twelve months. Net profit margin improved to 32.2% from 27.6% a year ago, signaling higher earnings quality and operational efficiency. Investors will note not only the company’s expanding profit margins, but also its attractive dividend, solid valuation, and consistently positive profit trajectory, with no major risks flagged in this period.

    See our full analysis for Dimeco.

    Next up, we’ll see how these headline results measure up against the widely held Simply Wall St narratives, spotlighting where the numbers match the market’s expectations and where they could spark new debates.

    Curious how numbers become stories that shape markets? Explore Community Narratives

    OTCPK:DIMC Earnings & Revenue History as at Oct 2025
    • Dimeco trades at $41.25 per share while the DCF fair value stands at $93.21, meaning shares are currently 56% below what the discounted cash flow model suggests they could be worth.

    • Bulls point to this sizable gap as a key opportunity, highlighting that the company’s price-to-earnings ratio is just 6.8x versus the US banks industry average of 11.2x.

      • They argue that such a low multiple, combined with resilient profit margins of 32.2%, significantly supports the bullish case that Dimeco is undervalued both absolutely and relative to peers.

      • Critics may note limited risk disclosures, but value-focused investors see few red flags to challenge the upside implied by the fair value gap.

    • Net profit margin climbed to 32.2%, outshining the previous year’s 27.6% and indicating Dimeco is extracting higher profitability than typical industry rivals.

    • The prevailing market view underscores how this margin strength aligns with past earnings growth of 6.7% per year.

      • What is notable is that the most recent year’s 36.1% profit surge reinforces this operational quality, rather than marking a one-off spike.

      • Combined with limited downside risks and consistent profit trajectory, the margin trend makes bullish arguments more compelling for fundamentals-driven investors.

    • Dimeco’s price-to-earnings ratio of 6.8x sits well below both the peer group average of 9.5x and the sector’s 11.2x, solidifying its profile as a value stock within US banks.

    • The prevailing market view highlights that this relative discount, alongside a history of profit or revenue growth, draws in investors seeking income and upside potential.

      • Not only is the P/E ratio lower, but it comes with a track record of growing profits and an attractive dividend, helping it stand out from pure deep value plays that lack quality.

      • Any debate about slow long-term growth is less pressing when the company has consistently improved margins and payout, according to the financial data presented.

    Continue Reading

  • Zoster vaccination in people with HIV linked to lower mortality and cardiovascular risk

    Zoster vaccination in people with HIV linked to lower mortality and cardiovascular risk

    Zoster vaccination was associated with significantly reduced risks for all-cause mortality and major adverse cardiovascular events (MACE) among people living with HIV (PLWH), according to data from a real-world matched cohort presented at 

    Continue Reading

  • A Look at Vertiv’s (VRT) Valuation Following Earnings Beat and Raised Full-Year Guidance

    A Look at Vertiv’s (VRT) Valuation Following Earnings Beat and Raised Full-Year Guidance

    Vertiv Holdings Co (NYSE:VRT) posted third-quarter earnings that outpaced expectations, prompting management to raise full-year guidance for both sales and earnings. The results highlight strong demand in digital infrastructure and AI-supported data centers.

    See our latest analysis for Vertiv Holdings Co.

    Vertiv’s momentum has been nothing short of remarkable. After topping expectations and lifting its forecast, shares have catapulted with a 31% gain in the past month alone, driving the 1-year total shareholder return to over 66%. With big data center contracts and fresh executive moves making headlines, investor enthusiasm continues to build as the company cements its leadership in AI-powered infrastructure.

    If this surge in data center demand has you curious about new opportunities, it’s a great moment to discover See the full list for free.

    Yet with shares already soaring and full-year guidance now higher, the big question for investors becomes this: Is Vertiv’s red-hot rally still leaving room for upside, or is the market already pricing in the next leg of growth?

    Vertiv’s last close of $186.06 stands noticeably above the narrative’s fair value estimate of $173.11, revealing a premium in current market enthusiasm versus calculated future prospects.

    Accelerating global demand for high-density, AI-driven data centers is driving robust growth in Vertiv’s sales pipeline and backlog. This is evidenced by recurring record order levels, backlog growth, and management’s raised organic sales growth guidance, which supports potentially higher future revenue.

    Read the complete narrative.

    Is this hot streak built to last? The most followed valuation hinges on a future profit windfall and a market-beating sales climb. But what exactly are the bold forecasts behind the scenes? Only the full narrative reveals the winning formula powering this price target.

    Result: Fair Value of $173.11 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent supply chain disruptions or a slowdown in AI data center build-outs could quickly test the strength of Vertiv’s growth outlook.

    Find out about the key risks to this Vertiv Holdings Co narrative.

    If you want to dive deeper or put your own spin on the story, you can build your own narrative from scratch in just a few minutes. Do it your way

    A great starting point for your Vertiv Holdings Co research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    Don’t miss your chance to gain an edge. Simply Wall Street highlights investment opportunities others overlook so you can position your portfolio ahead of the curve.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include VRT.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading